Wedbush Reiterates Outperform on Immunome, Maintains $33 Price Target

Benzinga · 10/25 15:06
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.